Aureus Asset Management LLC Takes Position in Insmed, Inc. $INSM

Aureus Asset Management LLC purchased a new position in Insmed, Inc. (NASDAQ:INSM) during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 6,000 shares of the biopharmaceutical company’s stock, valued at approximately $981,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. EverSource Wealth Advisors LLC increased its stake in Insmed by 65.6% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 664 shares of the biopharmaceutical company’s stock worth $67,000 after acquiring an additional 263 shares during the last quarter. First Trust Advisors LP boosted its position in shares of Insmed by 80.8% during the 2nd quarter. First Trust Advisors LP now owns 47,392 shares of the biopharmaceutical company’s stock valued at $4,770,000 after acquiring an additional 21,176 shares during the last quarter. Baird Financial Group Inc. bought a new stake in shares of Insmed during the 2nd quarter valued at about $2,589,000. Amundi grew its holdings in shares of Insmed by 21,194.4% during the second quarter. Amundi now owns 11,499 shares of the biopharmaceutical company’s stock worth $1,130,000 after purchasing an additional 11,445 shares in the last quarter. Finally, Natixis purchased a new position in shares of Insmed during the second quarter worth about $1,072,000.

Insider Buying and Selling at Insmed

In other Insmed news, CFO Sara Bonstein sold 2,404 shares of the business’s stock in a transaction on Wednesday, June 3rd. The shares were sold at an average price of $102.27, for a total value of $245,857.08. Following the completion of the sale, the chief financial officer directly owned 69,082 shares of the company’s stock, valued at $7,065,016.14. The trade was a 3.36% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO William Lewis sold 10,699 shares of the business’s stock in a transaction on Thursday, July 9th. The stock was sold at an average price of $117.40, for a total transaction of $1,256,062.60. Following the completion of the sale, the chief executive officer directly owned 259,058 shares of the company’s stock, valued at $30,413,409.20. This represents a 3.97% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 54,590 shares of company stock worth $5,793,738 over the last 90 days. Company insiders own 2.10% of the company’s stock.

Insmed Stock Performance

NASDAQ:INSM opened at $106.64 on Thursday. The company has a market capitalization of $23.11 billion, a price-to-earnings ratio of -18.55 and a beta of 0.78. The business has a 50 day moving average of $105.41 and a 200 day moving average of $134.22. The company has a debt-to-equity ratio of 0.80, a current ratio of 4.47 and a quick ratio of 4.10. Insmed, Inc. has a 1-year low of $90.39 and a 1-year high of $212.75.

Insmed (NASDAQ:INSM) last issued its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported ($0.76) EPS for the quarter, beating analysts’ consensus estimates of ($0.90) by $0.14. The business had revenue of $305.96 million for the quarter, compared to analysts’ expectations of $300.81 million. Insmed had a negative net margin of 144.44% and a negative return on equity of 130.11%. The business’s quarterly revenue was up 229.7% on a year-over-year basis. During the same period last year, the business earned ($1.42) earnings per share. On average, sell-side analysts predict that Insmed, Inc. will post -2.43 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on INSM. BMO Capital Markets began coverage on shares of Insmed in a research note on Monday. They issued an “outperform” rating and a $192.00 target price on the stock. Wells Fargo & Company boosted their price target on shares of Insmed from $160.00 to $161.00 and gave the stock an “overweight” rating in a research note on Wednesday, July 15th. HC Wainwright reissued a “buy” rating and issued a $220.00 price target on shares of Insmed in a report on Monday. Royal Bank Of Canada lowered their price objective on shares of Insmed from $205.00 to $195.00 and set an “outperform” rating on the stock in a research report on Friday, June 5th. Finally, Roth Capital reaffirmed a “buy” rating on shares of Insmed in a report on Monday, June 8th. Two analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Insmed presently has a consensus rating of “Buy” and an average price target of $209.13.

Insmed Company Profile

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.